STAT Plus: Startup TScan signs $30m deal with Novartis
RUBY WALLAU FOR STAT
By harnessing information from T cells in recovering cancer patients, TScan aims to essentially reprogram the same cells in other patients.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario